Lyra also reported success on key secondary endpoints. These included improvements in broader symptom scores and patient ...

Lyra's LYR-210 met key goals in a Phase 3 trial for chronic rhinosinusitis, showing early and sustained symptom relief with a ...

Cepacol® understands the discomfort that nasal congestion and sore throats can bring to your daily life and offers a wide ...

The rally comes after the biotech company announced that its drug candidate, LYR-210, delivered statistically significant ...

AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...

Shares of Lyra Therapeutics, Inc. (LYRA) rocketed 370% on Monday after the company announced positive results from its ...

Sanofi and Regeneron's fast-growing immunology drug Dupixent is on course for a third indication in Europe after being recommended for approval as a treatment for people with nasal polyps.

Lyra Therapeutics (NASDAQ:LYRA) saw its stock soar by 180% after releasing encouraging Phase 3 results for its lead ...

Market Overview: The Global Nasal Polyposis Drugs Market is expanding rapidly, owing to advances in biologic medicines, minimally invasive surgical procedures, and personalized medicine approaches.

CRSwNP recurrence after surgery is linked to high eosinophils, GERD, diabetes, and asthma. A new model accurately predicts ...

Lyra Therapeutics stock surged in premarket trading after announcing positive Phase 3 trial results for a key treatment.

Regeneron and SNY's itepekimab meets the primary endpoint in one COPD trial but misses in another, leaving future plans under review.